TY-2136
- Generic Name
- TY-2136
A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations
Phase 1
Recruiting
- Conditions
- Locally Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- TYK Medicines, Inc
- Target Recruit Count
- 282
- Registration Number
- NCT05769075
- Locations
- 🇺🇸
Oncology Consultants, Houston, Texas, United States
🇺🇸Rhode Island Hospital, Brown University, Providence, Rhode Island, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath